• Summary

    Acute Coronary Syndrome (ACS) represents a major cause of morbidity and mortality worldwide and
    in Egypt. The risk of a second event and the risk of mortality remains high especially early post-event
    which poses a demand for further research. Higher endothelial dysfunction, systemic inflammation,
    and oxidative stress where found to be factors related to an increased risk of a recurrent
    cardiovascular event in post-ACS patients. Pentoxifylline, as a non-selective inhibitor of
    phosphodiesterase (PDE), is an FDA-approved drug for the treatment of intermittent due to peripheral
    arterial disease. It was found by more than one study to have anti-inflammatory and anti-oxidant
    effects and to impart improvement on markers of endothelial dysfunction. The aim of this study is to
    study the effect of using pentoxifylline 400mg three times daily for 2 months on the markers of
    endothelial dysfunction, oxidative stress and inflammatory markers in post-ACS patients which if
    successful could have the benefit of decreasing the incidence of ACS reoccurrence, prevent
    deterioration in the patient's quality of life, and save costs for both the patient and the healthcare
    system.

  • Achievements


  • List of Publications from the Project


  • Partners

  • Project Members

  • Project Leaders

  • Project PI

    Asmaa Saeed

  • Faculty

    Faculty of Pharmacy

  • Research Group

  • Funding Agency

    STDF / STIFA

  • Funding Program

    Post Graduate Support Grant

  • Start Date

    2021-01-01

  • End Date

    2023-01-01

  • Project website